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ADAMTS13 is a reprolysin-type metalloproteinase belonging to the ADAMTS
(a disintegrin and metalloproteinase with thrombospondin type 1 motif) family.
It speciﬁcally cleaves plasma von Willebrand factor (VWF) and regulates
platelet adhesion and aggregation. ADAMTS13 is a multi-domain enzyme. In
addition to the N-terminal metalloproteinase domain, the ancillary domains,
including a disintegrin-like domain, a thrombospondin-1 type 1 repeat, a Cys-
rich domain and a spacer domain, are required for VWF recognition and
cleavage. In the present study, a fragment of the ADAMTS13 ancillary domains
(ADAMTS13-DTCS; residues 287–685) was expressed using CHO Lec cells,
puriﬁed and crystallized. Diffraction data sets were collected using the SPring-8
beamline. Two ADAMTS13-DTCS crystals with distinct unit-cell parameters
generated data sets to 2.6 and 2.8 A ˚ resolution, respectively.
1. Introduction
von Willebrand factor (VWF) is a plasma glycoprotein that is
involved in platelet-dependent haemostasis (Sadler, 1998). VWF is
primarily synthesized in vascular endothelial cells and megakaryo-
cytes and is released into the plasma as ultralarge multimeric forms
(UL-VWF) that are highly active in platelet adhesion and aggrega-
tion. A plasma metalloproteinase, ADAMTS13, speciﬁcally cleaves
the Tyr1605-Met1606 peptidyl bond within the A2 domain of VWF
(Dent et al., 1990). Cleavage of UL-VWF into smaller forms by
ADAMTS13 limits platelet thrombus formation. A deﬁciency of
ADAMTS13 enzymatic activity caused by either genetic mutations in
theADAMTS13geneoracquiredautoantibodiesagainst ADAMTS13
results in the accumulation of UL-VWF in plasma. This leads to the
formation of disseminated platelet-rich microthrombi in arterioles,
which is one of the characteristic pathogenic features of thrombotic
thrombocytopaenicpurpura (TTP),a life-threateningsystemic disease
(Tsai, 2009). Conversely, excessive cleavage of VWF causes von
Willebrand disease type 2A (Sadler, 2005).
Human ADAMTS13 consists of 1427 amino acids and has a
modular structure comprising a signal peptide, a short propeptide, a
metalloproteinase domain (M), a disintegrin-like domain (D), a
thrombospondin-1 type1 repeat (T1),a Cys-rich domain(C),a spacer
domain (S), seven additional type 1 repeats (T2–T8) and two CUB
(C1r/C1s, urinary epidermal growth factor, bone morphogenic
protein) domains (Levy et al., 2001; Soejima et al., 2001; Zheng et al.,
2001). C-terminal truncation of ADAMTS13 after the C but not the S
domain results in severe loss of proteolytic activity towards VWF
(Soejima et al., 2003; Zheng et al., 2003). Therefore, in addition to the
M domain, the ancillary domains including the D, T, C and S domains
(DTCS) are necessary for normal ADAMTS13 activity, although the
distal C-terminal domains are required for regulation of in vivo
thrombus formation under high-shear conditions (Banno et al., 2009).
We have previously reported a minimal functional substrate con-
sisting of 73 amino-acid residues of the C-terminal region of the VWF
A2 domain (Asp1596–Arg1668) and designated VWF73 (Kokame et
al., 2004; Miyata et al., 2007). A recent study has shown that the
VWF-binding exosites located in the T, C and S domains interact with
different segments of VWF73 (Gao et al., 2008). These interactions
increased the VWF-binding afﬁnity and rate of substrate cleavage by300-fold. At least 16 causative missense mutations for congenital TTP
and ﬁve missense polymorphisms in the ADAMTS13 gene have been
identiﬁed within the DTCS region (Levy et al., 2001; Kokame et al.,
2002; Banno & Miyata, 2008). Although most TTP-causative mutant
proteins are likely to show secretion deﬁciency, a P475S poly-
morphism variant showed normal secretion but reduced VWF-
cleaving activity (Kokame et al., 2002; Akiyama et al., 2008). Detailed
structural information on exosite-containing domains will help in
understanding the structure-based mechanism of substrate recogni-
tion and speciﬁcity and the effects of TTP-causative mutations and
common polymorphisms. To date, crystal structures of the M and D
domains of three human ADAMTS-family proteins, ADAMTS1,
ADAMTS4 and ADAMTS5, have been reported (Gerhardt et al.,
2007; Mosyak et al., 2008; Shieh et al., 2008). However, no crystal
structures of exosite-containing fragments of ADAMTSs have been
reported.
Here, we report the expression and puriﬁcation of the exosite-
containing human ADAMTS13-DTCS fragment using mammalian
CHO Lec cells with mutations in multiple glycosylation-related
genes. Proteins obtained from this cell line are suitable for crystal-
lization because their restricted and homogeneous glycosylation
improves the packing of the protein molecules. We also report the
results of our crystallization and preliminary X-ray studies of
ADAMTS13-DTCS.
2. Methods
2.1. Expression and purification of ADAMTS13-DTCS
An ADAMTS13 cDNA (AB069698) fragment corresponding to
amino-acid residues 287–685 (ADAMTS13-DTCS) was ampliﬁed by
PCR and cloned into a mammalian expression vector based on
pcDNA3.1/Myc-His (Invitrogen), which has a mouse Nid1 signal
sequence (Yasui et al., 2007). The nucleotide sequence was conﬁrmed
by dye-terminator sequencing. The ADAMTS13-DTCS fragment
expressed from this vector contains a tobacco etch virus (TEV)
proteinase cleavage site (Glu-Asn-Leu-Tyr-Phe-Gln/Gly) followed by
tandem His-tag sequences at the C-terminus. We transfected the
plasmid into CHO Lec 3.2.8.1 cells (Stanley, 1989) by electroporation
and selected colonies resistant to G418 (3 mg ml
 1) on 96-well plates
in  -minimal essential medium supplemented with 5% foetal bovine
serum for 10 d. ADAMTS13-DTCS levels in the media of 48 G418-
resistant colonies were examined by Western blotting with anti-
6 His antibody (Sigma–Aldrich, St Louis, Missouri, USA). The
clone with the highest secretion level of ADAMTS13-DTCS was
cultured in the medium containing 0.5 mg ml
 1 G418 by the roller-
bottle method and the medium was collected every 3 d. The
ADAMTS13-DTCS was recovered from the culture medium by
50%(w/v) ammonium sulfate precipitation and was puriﬁed by
Ni–NTA agarose chromatography (Sigma–Aldrich). The eluted
ADAMTS13-DTCS was incubated with TEV proteinase for 12 h at
297 K to remove the C-terminal tags. After dialysis in a buffer
consisting of 10 mM MES and 100 mM NaCl pH 6.0, the digest
was applied onto a Hi-Trap SP HP cation-exchange column (GE
Healthcare, Buckinghamshire, England). The column was washed
with the same buffer and ADAMTS13-DTCS was eluted with a linear
gradient of NaCl (0.1–0.7 M)i n1 0m M MES pH 6.0. Fractions were
analyzed by SDS–PAGE under reducing conditions (Fig. 1). The
fractions rich in ADAMTS13-DTCS (lanes 5 and 6) were combined,
dialyzed against 10 mM MES pH 6.0 and concentrated using a
Vivaspin-5 separation device (30 kDa molecular-weight cutoff;
Sartorius, Edgewood, New York, USA) to a ﬁnal concentration of
 10 mg ml
 1 for crystallization.
2.2. Crystallization screening
Initial screening for crystallization conditions for ADAMTS-DTCS
was carried out by the sitting-drop vapour-diffusion method using
Index Screen, SaltRx Screen, PEG/Ion Screen, Grid Screen MPD and
Grid Screen Ammonium Sulfate kits (Hampton Research, Aliso
Viejo, California, USA). A volume of 0.1 ml protein solution was
manually mixed with an equal amount of reservoir solution and the
droplets were allowed to equilibrate against 0.1 ml reservoir solution
at 293 K for 24 h.
2.3. Diffraction data collection
For X-ray measurements, crystals were soaked in a solution
containing 20% glycerol, 26% PEG 1500, 100 mM MES pH 6.0 for
cryoprotection prior to ﬂash-freezing and were immediately exposed
to a stream of nitrogen gas at 100 K. Preliminary X-ray data were
collected using an in-house X-ray diffractometer (Micromax-007
X-ray generator with an R-AXIS VII imaging-plate detector; Rigaku,
Tokyo, Japan) and diffraction-quality crystals were selected for data
acquisition using the SPring-8 beamline. All the diffraction data sets
were collected on beamline BL41XU at 100 K using an ADSC
Quantum 310R detector and the diffraction images were processed
using HKL-2000 software (Minor et al., 2006).
3. Results and discussion
3.1. Protein preparation
We ﬁrst attempted to express ADAMTS13-DTCS in Escherichia
coli and insect cells. The expressed ADAMTS13-DTCS formed
inclusion bodies and renaturation of ADAMTS13-DTCS did not
succeed. We then tried to express ADAMTS13-DTCS in mammalian
cells. As ADAMTS13-DTCS contains four potential N-glycosylation
sites, we used the CHO Lec 3.2.8.1 cell line for stable expression. This
cell line has four different mutated genes that are involved in the N-
and O-glycosylation pathways (Stanley, 1989). Preliminary experi-
ments showed that the endogenous signal and propeptide sequences
of ADAMTS13 resulted in low protein secretion. We replaced the
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Figure 1
SDS–PAGE analysis of ADAMTS13-DTCS fractions from Hi-Trap SP HP cation
chromatography. Proteins were analyzed by SDS–PAGE and stained with
Coomassie Brilliant Blue. Lanes 1 and 3, molecular-weight markers (kDa); lane
2, pooled Ni–NTA eluate treated with TEV proteinase; lanes 4–7, eluate fractions
Nos. 5–8, respectively, from the Hi-Trap SP HP column. Arrow, ADAMTS13-
DTCS. Asterisk, TEV proteinase.signal sequence and prosequence with the mouse Nid1 signal
sequence (Mann et al., 1989). This replacement dramatically
increased the secretion of ADAMTS13-DTCS into the medium.
ADAMTS13-DTCS was puriﬁed by Ni–NTA chromatography
followed by Hi-Trap SP cation-exchange chromatography. The
molecular weight of the recombinant protein, 45 kDa, estimated by
SDS–PAGE coincided well with the estimated molecular weight of
46 kDa (Fig. 1). Fractions (Fig. 1, lanes 5 and 6) from the Hi-Trap SP
column were combined and used for crystallization without further
puriﬁcation. Approximately 6 mg ADAMTS13-DTCS was recovered
from 20 l culture medium.
3.2. Crystallization
Of the 288 initial crystallization conditions tested, 20 yielded
microcrystals (Fig. 2a). Using solution No. 4 of the PEG/Ion Screen
kit [0.2 M lithium chloride, 20%(w/v) PEG 3350 pH 6.8] as a starting
condition, the pH of the mother liquor, the concentration and
molecular weight of the PEG and the species and concentrations of
salts and additives were optimized. The combination of reﬁnement of
the crystallization conditions and an increase in the protein concen-
tration (to  20 mg ml
 1) improved the size of the crystals. Single
crystals were obtained from drops made up of 0.5 ml protein solution
and 0.5 ml reservoir solution [26%(w/v) PEG 1500, 100 mM MES pH
6.0] supplemented with a one-ﬁfth volume of 40%(w/w) penta-
erythritol ethoxylate (3/4 EO/OH; Additive Screen solution No. 52;
Hampton Research). Crystals with dimensions of 300   100   50 mm
were formed after 3–7 d at 293 K (Fig. 2b).
3.3. X-ray analysis
All diffraction data sets were acquired using the oscillation method
on beamline BL41XU at a wavelength of 1.0 A ˚ . The oscillation angle
was 1.0  for all data sets. The native data sets for form 1 and form 2
contained 16 867 (2.60 A ˚ resolution) and 12 811 (2.80 A ˚ resolution)
unique reﬂections, respectively. The asymmetric unit was estimated to
contain one molecule, with corresponding crystal volume per protein
weights of 2.7 and 3.1 A ˚ 3 Da
 1 for crystal forms 1 and 2, respectively.
Solvent-content estimations based on a single copy of the molecule
per asymmetric unit gave values of 53.4% and 48.6% for crystal forms
1 and 2, respectively. The X-ray data showed that the two crystal
forms have different unit-cell parameters even when they are
obtained under identical conditions. The variation in crystal packing
might reﬂect the mobility of the domains in ADAMTS13-DTCS. The
statistics of the data sets are summarized in Table 1.
3.4. Screening of heavy-atom derivatives
We attempted experimental phasing using heavy-atom derivatives
because molecular replacement was not an option owing to the lack
of related structures. The limited availability of single large crystals
owing to the small amount of ADAMTS13-DTCS and its tendency to
form multiple crystals produced difﬁculties in the search for heavy-
atom derivatives. Therefore, we focused on investigating the
colouring of crystals on heavy-atom soaking, which can be a good
indication of heavy-atom binding. We selected 13 coloured com-
pounds (Au-6, M1-10, M-11, M1-14, M1-15, M1-16, M1-17, M2-2,
M2-3, M2-5, M2-16, M2-17 and M2-18) from Heavy Atom Screens
(Hampton Research) and soaked small crystals in reservoir solution
supplemented with each of these compounds. After several hours, we
found that three osmium-containing compounds, ammonium hexa-
bromoosmate (M2-16), potassium hexachloroosmate (M2-17) and
osmium chloride (M2-18), were heavily absorbed into the crystals. To
examine the X-ray diffraction from these potential derivatives, we
prepared larger single crystals. We checked these using the in-house
X-ray facility and well diffracting crystals were shipped for data
acquisition at SPring-8. Structural analysis is now in progress using
data obtained from the derivative soaked in the osmium chloride
solution.
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Figure 2
Crystals of human ADAMTS13-DTCS grown by the sitting-drop method. (a)
Microcrystals obtained from solution No. 4 of the PEG/Ion Screen kit. (b) Crystals
obtained using the optimized conditions. The scale bars indicate 0.1 mm.
Table 1
Data-collection statistics for ADAMTS13-DTCS crystals.
Values in parentheses are for the highest resolution shell. A single crystal was used for
measurement for each data set.
Form 1 Form 2
Space group C2 C2
Unit-cell parameters
a (A ˚ ) 152.7 138.6
b (A ˚ ) 52.9 51.4
c (A ˚ ) 76.2 76.4
  ( ) 111.4 106.7
Wavelength (A ˚ ) 1.0 1.0
Resolution (A ˚ ) 50–2.60 (2.69–2.60) 30–2.80 (2.90–2.80)
No. of unique reﬂections 16867 (1272) 12811 (1259)
Rmerge† 0.052 (0.176) 0.062 (0.403)
I/ (I) 19.3 (5.7) 13.3 (3.5)
Completeness (%) 95.3 (72.7) 99.5 (99.3)
Redundancy 3.5 (2.9) 3.7 (3.6)
Matthews value (A ˚ 3 Da
 1) 2.64 2.39









i IiðhklÞ, where Ii(hkl)i st h eith intensity
measurement of reﬂection hkl and hI(hkl)i is its weighted average.We thank M. Tomisako for her help with the crystallization
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